Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma-Reference-Cited by-同舟云学术

Comparison of Cilta-cel, an Anti-BCMA CAR-T Cell Therapy, Versus Conventional Treatment in Patients With Relapsed/Refractory Multiple Myeloma

Published:2021-10 Issue: Volume: Page:
ISSN:2152-2650
Container-title:Clinical Lymphoma Myeloma and Leukemia
language:en
Short-container-title:Clinical Lymphoma Myeloma and Leukemia

Author:

Costa Luciano J.^ORCID,Lin Yi^ORCID,Cornell R. Frank,Martin Thomas,Chhabra Saurabh,Usmani Saad Z.,Jagannath Sundar,Callander Natalie S.,Berdeja Jesus G.,Kang Yubin^ORCID,Vij Ravi,Godby Kelly N.,Malek Ehsan,Neppalli Amarendra,Liedtke Michaela^ORCID,Fiala Mark,Tian Hong,Valluri Satish^ORCID,Marino Jennifer^ORCID,Jackson Carolyn C.,Banerjee Arnob,Kansagra Ankit^ORCID,Schecter Jordan M.,Kumar Shaji,Hari Parameswaran

Publisher

Elsevier BV

Subject

Cancer Research,Oncology,Hematology

Reference22 articles.

1. Multiple myeloma: patient outcomes in real-world practice;Yong;Br J Haematol,2016

2. Outcomes of patients with multiple myeloma refractory to CD38-targeted monoclonal antibody therapy;Gandhi;Leukemia,2019

3. Belantamab mafodotin for relapsed or refractory multiple myeloma (DREAMM-2): a two-arm, randomised, open-label, phase 2 study;Lonial;Lancet Oncol,2020

4. Oral selinexor-dexamethasone for triple-class refractory multiple myeloma;Chari;N Engl J Med,2019

5. Melflufen and dexamethasone in heavily pretreated relapsed and refractory multiple myeloma;Richardson;J Clin Oncol,2021

Cited by 32 articles. 订阅此论文施引文献订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献

1. Externally Controlled Studies Using Real-World Data in Patients With Hematological Cancers;JAMA Oncology;2024-08-29

2. Efficacy of ixazomib, lenalidomide, dexamethasone regimen in daratumumab‐exposed relapsed/refractory multiple myeloma patients: A retrospective analysis;European Journal of Haematology;2024-08-26

3. From spear to trident: Upgrading arsenal of CAR-T cells in the treatment of multiple myeloma;Heliyon;2024-05

4. Long-term remission and survival in patients with relapsed or refractory multiple myeloma after treatment with LCAR-B38M CAR T cells: 5-year follow-up of the LEGEND-2 trial;Journal of Hematology & Oncology;2024-04-24

5. Chimeric antigen receptor (CAR) modified T Cells in acute myeloid leukemia: limitations and expectations;Frontiers in Cell and Developmental Biology;2024-04-17